Altogether, these findings suggest that p300/CBP complexes retain their acetyltransferase activity for the H2BNT lysine residues despite the inhibition of the bromodomain, which sustains oncogenic enhancer activity in prostate cancer. Here, CREBBP is linked to prostate cancer.